The J.P. Morgan Healthcare Conference got off to a rousing start with the announcement of several deals on the first day, but the overall tone of the meeting was subdued as investors continued to worry about how some of the biggest names in pharma will navigate looming patent cliffs, a lack of bigger M&A, the financing environment for smaller biotechs, and an uncertain US policy outlook under a new administration.
Deals And Sunshine At J.P. Morgan, But Biopharma Outlook Remains Mixed
Initial excitement over a few small deals announced at the opening of J.P. Morgan tapered off as approaching exclusivity losses, a lack of big takeouts and political uncertainty weighed on sentiment.
